B+
Bull case
25%
Probability
Target price
$36.00
Analysis reference price unavailable
Analysis 2026-05-15 · RankAlpha Sentiment Codex
QURE
uniQureFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$30.00
Analysis reference price unavailable
Analysis 2026-05-15 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$20.00
Analysis reference price unavailable
Analysis 2026-05-15 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-05-15
Recent news sentiment (30D)
+0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+22.4
Score
AI commentary
Tone remains cautiously constructive but monitoring-oriented rather than fully bullish. The primary May 5 company update confirmed milestone timing and a long cash runway, and QURE closed at $27.75 on May 14, 2026 with shares at $27.22 intraday on May 15, 2026, suggesting the post-print reaction has not collapsed. Still, delayed analyst-revision evidence is sparse, consensus/revenue-surprise reporting is mostly from secondary earnings pages, and low coverage means the stock can stay volatile around each AMT-130 and AMT-260 headline.
RankAlpha Sentiment Codex - 2026-05-15
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-20catalystPost-earnings digestion tests whether Q1 updates can hold the stock above pre-print levelsHigh impact
The May 5 earnings update kept the core AMT-130, AMT-260 and cash-runway milestones intact, with $586.6 million of cash, cash equivalents and current investment securities and runway into the second half of 2029, while Q1 revenue was $3.6 million and net loss was $53.5 million [#8-K-2026-05-05] [#10-Q-2026-05-05]. Secondary post-print coverage is thin; one checked earnings page showed a modest EPS beat versus consensus but a revenue miss, and delayed analyst revision evidence remained sparse, so near-term sentiment likely depends on whether investors focus on runway and milestone cadence rather than the still-lossmaking profile.
2026-06-18eventAMT-260 first-cohort epilepsy update at the Epilepsy Foundation Pipeline ConferenceHigh impact
uniQure said it expects to present Phase I/IIa data from the first six AMT-260 patients with up to six months of follow-up at the Epilepsy Foundation Pipeline Conference on June 18-19, 2026, giving investors a nearer-term clinical readout outside Huntington's disease [#8-K-2026-05-05].
2026-06-30eventAMT-130 regulatory path clarity from FDA Type B meeting and UK filing trackHigh impact
Management said a Type B FDA meeting is scheduled for Q2 2026 to discuss a potential new AMT-130 trial design and the statistical analysis plan for the four-year data expected in Q3 2026, while a UK MAA remains on track for Q3 2026 after a constructive MHRA pre-submission meeting [#8-K-2026-05-05] [#10-Q-2026-05-05]. This remains the highest-value catalyst because U.S. approval evidence requirements are still unsettled.
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-15 • Updated nightlySource: Internal modelMethodology